Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
IMP-1734 by Eikon Therapeutics for Solid Tumor: Likelihood of Approval
IMP-1734 is under clinical development by Eikon Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Data Insights
IMP-1734 by Eikon Therapeutics for Peritoneal Cancer: Likelihood of Approval
IMP-1734 is under clinical development by Eikon Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...